MUVON Therapeutics is advancing regenerative medicine and breaking taboos in women’s health. CEO and Co-Founder Deana Mohr shares, among other things, how the Zurich-based spin-off turns research into clinical impact – thanks to close collaborations with partners like the University Hospital, ETH, and Wyss Zurich Translational Center.
This Swiss clinical-stage biotechnology company aims to revolutionize the treatment of various diseases based on muscle degeneration and damage by using the body’s own cells. Their first therapeutic focus is the treatment of stress urinary incontinence in women (phase II) and men (preclinical).
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information